awmsg logo



atazanavir (Reyataz®)


Reference No. 746

Publication date:
03/02/2011


Appraisal information

atazanavir (Reyataz®) capsule


Company: Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category: Infections
NMG meeting date: 17/11/2010
AWMSG meeting date: 15/12/2010
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1810
Ministerial ratification: 27/01/2011

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Atazanavir (Reyataz®) capsules, co-administered with low dose ritonavir, are recommended as an option for use within NHS Wales for the treatment of HIV-1 infected paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products. Atazanavir (Reyataz®) is not suitable for shared care within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download